---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-065663"
form_type: "8-K"
ticker: "LIMN"
cik: "0001971387"
company_name: "Liminatus Pharma, Inc."
filed_at: "2025-07-03T23:59:59+00:00"
generated_at: "2026-05-18T09:31:35.916547+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Liminatus Pharma forms consortium for pancreatic cancer blood diagnostic with >95% sensitivity

## Summary
- Signed MOU with Samda Biolab and INNOCS AI to develop a blood-based diagnostic kit for early pancreatic cancer detection.
- Combined CA19-9 and INNOCS platform achieved >95% sensitivity and >99% specificity in a 1,086-subject cohort.
- Liminatus will lead regulatory filings with FDA and KMFDS upon commercialization phase.
- Global pancreatic cancer diagnostics market projected at $3B by 2026; blood-based segment >$700M.
- Consortium to leverage AI, biomarker platform, and Liminatus's regulatory/commercial infrastructure.

## SEC filing metadata
- accession: 0001104659-25-065663
- form_type: 8-K
- ticker: LIMN
- cik: 0001971387
- company_name: Liminatus Pharma, Inc.
- filed_at: 2025-07-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971387/000110465925065663/0001104659-25-065663-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971387/000110465925065663/tm2519876d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-065663
- JSON: https://secwatch.observer/filing/0001104659-25-065663.json
- Plain text: https://secwatch.observer/filing/0001104659-25-065663.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.